KV's Gestiva Reemerges With New Name, Makena, And A Long-Sought FDA Approval

Approval of the pre-term birth prevention therapy could pull KV Pharmaceutical back from the brink.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet